ATI 1013
Alternative Names: ATI-1013Latest Information Update: 25 Apr 2023
At a glance
- Originator Antidote Therapeutics
- Class Drug withdrawal therapies; Monoclonal antibodies
- Mechanism of Action Nicotinic antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chronic limb-threatening ischemia; Smoking withdrawal; Thromboangiitis obliterans
Most Recent Events
- 25 Apr 2023 ATI 1013 is still in preclinical trials for Chronic limb threatening ischemia, Smoking withdrawl, Thromboangitis obliterans in USA (Parenteral) (Antidote Therapeutics pipeline, April 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Peripheral-vascular-disorders in USA (Parenteral)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (Parenteral)